Compare Amgen, Inc. (AMGN) vs Garmin Ltd. (GRMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Garmin Ltd. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Garmin Ltd. trades at $242.7 (market cap $46.89B). The key difference: Amgen, Inc. is far larger — about 4.2× Garmin Ltd.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | GRMN | |
|---|---|---|
Market Cap | $196.12B | $46.89B |
Sector | Health | Technology |
52-Week High | $388.16 | $267.52 |
52-Week Low | $271.18 | $187.10 |
Enterprise Value | $241.41B | $44.35B |
Dividend Yield | 2.77% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Garmin (GRMN) trades at $243.11, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with 2025 revenue of $7.25B and net income of $1.66B, maintaining robust profitability margins. Recent product launches in aviation and marine electronics highlight ongoing innovation. The stock is near its consensus price target of $282.67, indicating potential upside from current levels.
The outlook for GRMN remains positive driven by consistent earnings beats and dividend stability, though valuation multiples appear elevated. Key risks include competitive pressures in consumer electronics and reliance on discretionary spending. Analyst sentiment is cautious with 74% hold ratings, suggesting balanced risk-reward near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
